Recently_1777294237270_124456903.png&w=64&q=75)
Source:
الوطن
AstraZeneca profit up 23%
AstraZeneca’s net profit rose 23% in the third quarter of 2026 to $3.12 billion, driven by growth in cancer drug sales. Revenue increased 7% to $16.21 billion. Oncology sales rose 17% to about $7.8 billion, supported by Tagrisso and Imfinzi, despite a 25% decline in Farxiga sales. The company launched a restructuring program targeting $1.5 billion in annual pre-tax savings and reaffirmed its forecast for revenue growth and earnings-per-share growth in 2026.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)